BSTG Biostage Inc.

Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$3.30    OTCQB
As of 01/24/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  10/28/2013
Outstanding shares:  10,760,871
Average volume:  6,233
Market cap:   $35,510,874
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   17.43
PS ratio:   0.00
Return on equity:   -153.61%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy